Skip to main content

Table 1 Study group averages of SUVBW and tissue-to-muscle (TiMr) and tissue-to-blood (TiBr) ratios (±2 SD) at 2 h and 4 h p.i. for various tissues

From: Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer

Tissue type

SUVBW

TiMr

TiBr

2 h

4 h

2 h

4 h

2 h

4 h

Fat

0.27 ± 0.07

0.18 ± 0.08

0.29 ± 0.05

0.28 ± 0.09

0.28 ± 0.06

0.27 ± 0.10

Liver

1.28 ± 0.40

1.02 ± 0.23

1.54 ± 0.61

1.93 ± 1.12

1.48 ± 0.62

1.88 ± 0.89

Lung

0.24 ± 0.11

0.16 ± 0.10

0.25 ± 0.08

0.24 ± 0.12

0.24 ± 0.08

0.23 ± 0.09

Muscle

0.95 ± 0.28

0.67 ± 0.34

0.96 ± 0.18

0.98 ± 0.28

Tumor

0.93 ± 0.56

0.72 ± 0.56

0.98 ± 0.46

1.09 ± 0.82

0.93 ± 0.35

1.02 ± 0.45

Tumor, viable

1.07 ± 0.63

0.86 ± 0.67

1.12 ± 0.49

1.29 ± 0.98

1.07 ± 0.36

1.21 ± 0.52

Tumor, high

1.22 ± 0.75

1.04 ± 0.83

1.28 ± 0.71

1.61 ± 1.58

1.22 ± 0.54

1.50 ± 0.96

Tumor, mid

0.96 ± 0.66

0.74 ± 0.54

1.00 ± 0.55

1.12 ± 0.79

0.95 ± 0.43

1.05 ± 0.39

Tumor, low

0.39 ± 0.52

0.33 ± 0.40

0.43 ± 0.59

0.62 ± 1.04

0.41 ± 0.51

0.55 ± 0.70